Fig. 7: Targeting GPX2 mitigates EGFR-TKI resistance in vivo. | Cell Death & Disease

Fig. 7: Targeting GPX2 mitigates EGFR-TKI resistance in vivo.

From: N6-methyladenosine-modified GPX2 impacts cancer cell stemness and TKI resistance through regulating of redox metabolism

Fig. 7

A Schematic overview illustrating the establishment and treatment of CDX model. B Tumor size was measured every 2 days. C Representative images of tumors tissues from the CDX model. D Tumor weight of each group at the end point. GSH level (E) and NADP + /NADPH ratio (F) of tumor tissues in different treatment groups were detected. G Immunohistochemical staining of GPX2, GLI1 and CD133. Scale bar, 50 µm. H Scoring for immunohistochemical staining was calculated. ***P < 0.001.

Back to article page